STOCK TITAN

WallachBeth Capital Announces Bullfrog AI Pricing of $5.7 Million Public Offering

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
WallachBeth Capital LLC announced that BullFrog AI Holdings, Inc. priced an underwritten public offering of 1,507,139 shares of common stock and accompanying warrants, with gross proceeds of approximately $5,700,000. The offering is expected to close on February 5, 2024, subject to customary closing conditions.
Positive
  • None.
Negative
  • None.

Insights

The recent public offering by BullFrog AI Holdings, Inc. is a strategic move to raise capital, indicative of the company's growth trajectory and future investment in its AI-driven drug development initiatives. The pricing of the offering at $3.782 per share, with gross proceeds of approximately $5.7 million, is a significant infusion of funds for a company in the biotech sector, where R&D costs are notably high. The offering's structure, including common stock and warrants, provides investors with potential for future equity participation, which could be seen as an incentive to invest.

From a financial perspective, the underwriting discounts and offering expenses will impact the net proceeds, which are crucial for the company’s operational funding. The additional 45-day option for underwriters to cover over-allotments could potentially bring in more capital, mitigating the risk of under-subscription. However, it's important to consider the dilutive effect on current shareholders, as the increase in outstanding shares could lead to earnings per share dilution.

Within the competitive landscape of biotech companies leveraging AI for drug development, BullFrog AI Holdings, Inc.'s public offering could signal to the market a robust confidence in their technology and pipeline. The adoption of AI and machine learning in pharmaceutical research is a growing trend aimed at reducing time and costs associated with drug discovery and development. The capital raised could accelerate BullFrog's research endeavors and potentially lead to quicker go-to-market strategies for their products.

It is also worth noting the timing of the offering. If the biotech sector is experiencing bullish sentiments, the offering could benefit from market momentum. Conversely, if the sector is bearish, the offering might face challenges. Market reception to similar offerings and the current performance of biotech stocks should be analyzed to anticipate potential market behavior post-offering.

From a legal standpoint, the effectiveness of the registration statement on Form S-1 with the SEC is a critical step for BullFrog AI Holdings, Inc. to comply with federal securities laws. This compliance allows the company to publicly offer its securities and provides investors with essential information through the prospectus. The availability of the final prospectus is crucial for transparency, enabling investors to make informed decisions based on detailed information about the offering, the company’s financial position and risk factors.

The 45-day option for underwriters to purchase additional shares also has legal implications, as it must be structured in accordance with SEC regulations to prevent market manipulation. Overall, legal compliance in these offerings serves to protect both the company and potential investors.

JERSEY CITY, N.J., Feb. 1, 2024 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) a technology-enabled drug development company using (AI) and machine learning to enable the successful development of pharmaceuticals and biologics priced an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase an additional 226,071 shares of common stock (and/or Pre-Funded Warrants in lieu thereof) and/or warrants to purchase 226,071 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.

The offering is expected to close on February 5, 2024, subject to satisfaction of customary closing conditions.

WallachBeth Capital, LLC is acting as sole book-running manager for the offering.

A registration statement on Form S-1 (File No. 333-276740) relating to the securities was filed with the Securities and Exchange Commission ("SEC") and became effective on January 31, 2024. This offering is being made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained, when available, from WallachBeth Capital, LLC, via email: cap-mkts@wallachbeth.com, or by calling +1 (646) 237-8585, or by standard mail at WallachBeth Capital, LLC, Attn: Capital Markets, 185 Hudson St, Jersey City, NJ 07311, USA. In addition, a copy of the final prospectus, when available, relating to the offering may be obtained via the SEC's website at www.sec.gov.

About WallachBeth Capital LLC

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-bullfrog-ai-pricing-of-5-7-million-public-offering-302050838.html

SOURCE WallachBeth Capital LLC

FAQ

What is the offering price of BullFrog AI Holdings, Inc. common stock?

The public offering price of BullFrog AI Holdings, Inc. common stock is $3.782 per share.

How many shares of common stock are included in the offering?

The offering includes 1,507,139 shares of common stock.

What is the expected gross proceeds from the offering?

The gross proceeds from the offering are approximately $5,700,000.

When is the offering expected to close?

The offering is expected to close on February 5, 2024, subject to customary closing conditions.

Who is the sole book-running manager for the offering?

WallachBeth Capital, LLC is acting as the sole book-running manager for the offering.

Bullfrog AI Holdings, Inc.

NASDAQ:BFRG

BFRG Rankings

BFRG Latest News

BFRG Stock Data

18.38M
6.17M
29.2%
3.48%
3.28%
Health Information Services
Pharmaceutical Preparations
Link
United States of America
GAITHERSBURG